|
|
Article: Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis.
- Article from:
- Blood Weekly
- Article date:
- November 12, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Intercept Pharmaceuticals, Inc., announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC). The study evaluated the effects of adding one of three doses of INT-747 or placebo to ursodeoxycholic acid (UDCA) therapy in patients who did not respond adequately to UDCA therapy alone. All three doses of INT-747 added to UDCA produced a statistically highly significant reduction in alkaline phosphatase (Alk Phos) levels, the primary endpoint at the end of the 12-week treatment period, as compared to patients receiving placebo and UDCA. Alk Phos is a liver enzyme routinely ...
Related newspaper, magazine, and journal articles:
|
|
Article: Liver and Metabolic Disease Company Intercept ...
PR Newswire;
October 26, 2004 ;
700+ words
... ... PRNewswire/ -- Intercept Pharmaceuticals, Inc., an ... compound, INT-747, is ... 312. About Intercept Pharmaceuticals New York City-based Intercept Pharmaceuticals, Inc. is ... candidate, INT-747 (6ECDCA ...
|
|